Biotech Investment Products
Biotech Investing
Biotechnology Research
About Us

Opportunities in
Tomorrow’s Biotech

By evaluating the most promising medical and scientific research, InvestBio seeks to single out the best venture capital and private equity opportunities for our clients.

Biotech venture capital is the driving force behind the funding of cutting edge technologies and current advances in the field of medical science. The potential reward of a successful biotech drug or treatment that reaches blockbuster status is enormous; not only to patients and the medical community, but to our qualified investors as well.

To achieve this, InvestBio identifies, selects, structures and manages these targeted opportunities, allowing us to create a rewarding outcome for all parties involved.

Searching for the
Most Promising Drugs

InvestBio is solely dedicated to seeking out and investing in life saving and enhancing drug treatments.  Our executive and advisory network’s broad scientific and medical experience allows us to identify the most promising research available.  Accessing this knowledge base and sifting through the research enables us to do what most investors can’t.  This is the first step we take in determining which opportunities we’re likely to support in the future.

Choosing the
Most Promising Opportunities

After identifying possible investment opportunities, InvestBio thoroughly investigates the history, management, financials, and marketing potential necessary to identify which drugs or treatments are the best choices to invest in.

Building a Foundation
for a Profitable Relationship

After completing a thorough selection process, and having chosen a company with the highest likelihood of success, we are able to level the playing field for our investors. InvestBio structures investment partnerships which allow our investors to participate in opportunities that were traditionally available only to institutional investors.

Successfully Working
Together to Accomplish Goals

As InvestBio typically invests alongside our clients, our communication needs are the same.  We pride ourselves on our ability to gain access to company’s management as well as providing direct access for our investors.   InvestBio manages these relationships on a day-to-day basis in an effort to maximize our partnership’s value.  For us, information is key.  Good, bad, or indifferent, we want to keep our investors informed with up-to-date information directly from our client companies. 

InvestBio often seeks board representation or access to company’s management in an effort to provide the most current information available to our investors.

FDA Grants Orphan Status to Clavis Pharma's Pancreatic Cancer Drug

Friday, January 8 2010; Therapeutics Daily
Norwegian firm Clavis Pharma ASA (OSL: CLAVIS) said today that its drug candidate Intravenous CP-4126 has been granted Orphan Drug Designation for the treatment of pancreatic cancer by the US Food and Drug Administration (FDA)
.
more >>

Sizzling market heats up biotech buyout fever

December 8, 2009; Fierce Biotech
Biotech buyouts are all the rage these days. Following fast on the heels of yesterday's news that
.
more >>

Trellis, MedImmune ink antibody deal

December 1, 2009; San Francisco Business Times
Trellis Bioscience Inc. sold a worldwide exclusive license that allows AstraZeneca plc’s MedImmune unit to develop and commercialize antibodies focused on respiratory syncytial virus